Abemaciclib hindered MCF-7 and MDA-MB-231 breast cancer cell growth and enhanced RT by inducing cell cycle arrest through the inhibition of CDK4 and CDK6 expression and increasing apoptosis. This evidence concerns the gene CDK4 and breast carcinoma.